

Ehlers-Danlos Syndromes: Revised Nosology, Villefranche, 1997

Peter Beighton,¹ Anne De Paepe,² Beat Steinmann,³ Petros Tsipouras,^{4*} and Richard J. Wenstrup⁵

¹Department of Human Genetics, University of Cape Town, Cape Town, South Africa

²Center for Medical Genetics, University Ghent, Ghent, Belgium

³Division of Metabolic and Molecular Diseases, University Children's Hospital, Zurich, Switzerland

⁴Department of Pediatrics, University of Connecticut Health Center, Farmington, Connecticut

⁵Division of Human Genetics, Children's Hospital Research Foundation, Cincinnati, Ohio

Categorization of the Ehlers-Danlos syndromes began in the late 1960s and was formalized in the Berlin nosology. Over time, it became apparent that the diagnostic criteria established and published in 1988 did not discriminate adequately between the different types of Ehlers-Danlos syndromes or between Ehlers-Danlos syndromes and other phenotypically related conditions. In addition, elucidation of the molecular basis of several Ehlers-Danlos syndromes has added a new dimension to the characterization of this group of disorders. We propose a revision of the classification of the Ehlers-Danlos syndromes based primarily on the cause of each type. Major and minor diagnostic criteria have been defined for each type and complemented whenever possible with laboratory findings. This simplified classification will facilitate an accurate diagnosis of the Ehlers-Danlos syndromes and contribute to the delineation of phenotypically related disorders. *Am. J. Med. Genet.* 77:31–37, 1998. © 1998 Wiley-Liss, Inc.

KEY WORDS: Ehlers-Danlos syndromes; diagnosis; joint hypermobility; skin extensibility; tissue fragility; arterial rupture; heritable disorders of connective tissue

INTRODUCTION

The Ehlers-Danlos syndromes (EDS) are a heterogeneous group of heritable connective tissue disorders characterized by articular hypermobility, skin extensibility, and tissue fragility.

Classification of EDS began in the late 1960s [Beighton, 1970; McKusick, 1972], and in 1986 a nosology was proposed at a meeting in Berlin which formalized the nomenclature of the various types [Beighton et al., 1988]. Recent developments in the elucidation of the biochemical and molecular bases of EDS, together with increasing clinical experience, now permit refinement of the existing nosology. We met in June 1997 at Villefranche-sur-Mer, France, in order to discuss revision of the classification. Our proposals, which form the subject of this communication, have the aim of facilitating development and improvement in the following aspects of EDS: 1) diagnostic uniformity for clinical and research purposes, 2) natural history, 3) management, 4) genetic counseling, and 5) identification of potential areas of research.

We propose a new, simplified classification of EDS into six major types. Our guiding principle in formulating the proposed classification was its usefulness to the "generalist." For each type we defined major and minor diagnostic criteria. A major criterion has high diagnostic specificity because it is infrequent in other conditions and in the general population. The presence of one or more major criteria is either necessary for clinical diagnosis or highly indicative and warrants laboratory confirmation whenever possible. A minor criterion is a sign of lesser diagnostic specificity. The presence of one or more minor criteria contributes to the diagnosis of a specific type of EDS. However, in the absence of major criteria they are not sufficient to establish the diagnosis. The presence of minor criteria might be suggestive of the diagnosis of (an) EDS-like condition(s), the nature of which will be elucidated when the molecular basis becomes known.

METHODS

The authors arrived at the proposed classification through a review of known clinical data and of bio-

Contract grant sponsor: Ehlers-Danlos National Foundation, USA; Contract grant sponsor: Ehlers-Danlos Support Group, UK. Each author contributed equally.

*Correspondence to: Petros Tsipouras, M.D., Department of Pediatrics, University of Connecticut Health Center, 263 Farmington Ave., Farmington, CT 06030. E-mail: tsipouras@nso1.uhc.edu

Received 5 August 1997; Accepted 3 September 1997

chemical and molecular observations obtained since the Berlin nosology meeting. This document was then circulated to other professionals working in the field for review and criticism.

REVISED CLASSIFICATION

A) General Comments

1. *Skin hyperextensibility* should be tested at a neutral site, meaning a site not subjected to mechanical forces or scarring, e.g., the volar surface of the forearm. It is measured by pulling up the skin until resistance is felt. In young children it is difficult to assess because of the abundance of subcutaneous fat [Beighton, 1993; Steinmann et al., 1993].

2. *Joint hypermobility* should be assessed using the Beighton scale [Beighton et al., 1983]. Joint hypermobility depends on age, gender, family, and ethnic background. A score of 5/9 or greater defines hypermobility. The total score is obtained by:

- a) passive dorsiflexion of the little fingers beyond 90°; one point for each hand;
- b) passive apposition of the thumbs to the flexor aspect of the forearm; one point for each hand;
- c) hyperextension of the elbows beyond 10°; one point for each elbow;
- d) hyperextension of the knees beyond 10°; one point for each knee; and
- e) forward flexion of the trunk with knees fully extended so that the palms of the hand rest flat on the floor; one point.

3. *Easy bruising* manifests as spontaneous ecchymoses, frequently recurring in the same areas, and causing characteristic brownish discoloration. Easy bruising may be the presenting symptom in early childhood. Child abuse should be considered in the differential diagnosis. There is a tendency toward prolonged bleeding in spite of normal coagulation status [Beighton, 1993; Steinmann et al., 1993].

4. *Tissue fragility* manifests as easy bruising and the presence of dystrophic scars. Scars are found mostly on pressure points (e.g., knee, elbow, forehead, or chin) and have a thin, atrophic papyraceous appearance. Frequently the scars become wide and discolored; wound healing is impaired [Beighton, 1993; Steinmann et al., 1993].

5. *Mitral valve prolapse (MVP) and proximal aortic dilatation* should be diagnosed by echocardiography, CT, or MRI. Mitral valve prolapse is a common manifestation, but aortic dilatation is uncommon; in a small proportion of patients with EDS it may be progressive [Leier et al., 1980]. Dilatation of the aortic root should be diagnosed when the maximum diameter at the sinuses of Valsalva exceeds the upper normal limits for age and body size [Roman et al., 1989, 1993]. Stringent criteria should be used for the diagnosis of MVP [Devereaux et al., 1987]. In those individuals where aortic dilatation exists, annuloaortic ectasia needs to be considered in the differential diagnosis.

6. *Chronic joint and limb pain* is common, and skeletal radiographs are normal [Sacheti et al., 1997]. Fre-

quently it is difficult to establish the precise anatomical localization of the pain.

7. Although well defined, the *kyphoscoliosis*, *arthrochaliasia*, and *dermatosparaxis* types are considerably less common than the classical, hypermobility, and arterial types [Beighton, 1993; Steinmann et al., 1993].

B) Classification

1) Classical type.

i) Inheritance.

Autosomal dominant.

ii) Major diagnostic criteria.

Skin hyperextensibility.

Widened atrophic scars (manifestation of tissue fragility).

Joint hypermobility.

iii) Minor diagnostic criteria.

Smooth, velvety skin.

Molluscoid pseudotumors.

Subcutaneous spheroids.

Complications of joint hypermobility (e.g., sprains, dislocations/subluxations, pes planus) [Beighton and Horan, 1969].

Muscle hypotonia, delayed gross motor development.

Easy bruising.

Manifestations of tissue extensibility and fragility (e.g., hiatal hernia, anal prolapse in childhood, cervical insufficiency) [Steinmann et al., 1993].

Surgical complications (postoperative hernias) [Beighton and Horan, 1960; Steinmann et al., 1993].

Positive family history.

iv) *Cause and laboratory diagnosis.* Abnormal electrophoretic mobility of the pro α 1(V) or pro α 2(V) chains of collagen type V has been detected in several but not all families with the classical type of EDS. Because a highly sensitive screening method has not yet been developed, the absence of detected abnormalities by biochemical or molecular analysis does not rule out a defect in collagen type V. In informative families, genetic linkage studies can be used for prenatal and postnatal diagnosis. Mutation analysis in individuals is being performed on a research basis. Locus heterogeneity has been documented [Steinmann et al., 1993]. Genetic linkage to intragenic markers of the COL5A1 or COL5A2 genes has been excluded in some families. Abnormalities in the collagen fibril structure can be found in many families by electron microscopy [Vogel et al., 1979]; a "cauliflower" deformity of collagen fibrils is characteristic [Hausser and Anton-Lamprecht, 1994] but not specific.

v) Special comments.

1. The skin manifestations range in severity; families with mild, moderate, and severe expression have been described (Table I).
2. Molluscoid pseudotumors are fleshy lesions asso-

TABLE I. Classification of Ehlers-Danlos Syndromes

New	Former	OMIM	Inheritance
Classical type	Gravis (EDS type I)	130000	AD
	Mitis (EDS type II)	130010	AD
Hypermobility type	Hypermobility (EDS type III)	130020	AD
Vascular type	Arterial-ecchymotic (EDS type IV)	130050	AD
		(225350) (225360)	
Kyphoscoliosis type	Ocular-Scoliotic (EDS type VI)	225400	AR
		(229200)	
Arthrochalasia type	Arthrochalasia multiplex congenita (EDS types VIIA and VIIB)	130060	AD
Dermatosparaxis type	Human dermatosparaxis (EDS type VIIC)	225410	AR
Other forms	X-linked EDS (EDS type V)	305200	XL
	Periodontitis type (EDS type VIII)	130080	AD
	Fibronectin-deficient EDS (EDS type X)	225310	?
	Familial hypermobility syndrome (EDS type XI)	147900	AD
	Progeroid EDS	130070	?
	Unspecified forms		—

ciated with scars. They are frequently found over pressure points (e.g., elbows).

3. Spheroids are small subcutaneous spherical hard bodies, frequently mobile and palpable on the forearms and shins. Spheroids may be calcified and detectable radiologically.
4. Recurrent joint subluxations are frequent in the shoulder, patella, and temporomandibular joints.
5. Dyspareunia and sexual dysfunction are occasional complaints in the classical and other types of EDS [Sorokin et al., 1994].
6. Fatigue is a frequent complaint.
7. For management, see Steinmann et al. [1993].

2) *Hypermobility type.*

i) Inheritance.

Autosomal dominant.

ii) Major diagnostic criteria.

Skin involvement (hyperextensibility and/or smooth, velvety skin).
Generalized joint hypermobility.

iii) Minor diagnostic criteria.

Recurring joint dislocations.
Chronic joint/limb pain.
Positive family history.

iv) Special comments.

1. Skin extensibility is variable. The presence of atrophic scars in individuals with joint hypermobility suggests the diagnosis of classical type.
2. Joint hypermobility is the dominant clinical manifestation. Certain joints, such as the shoulder, patella, and temporomandibular joints, dislocate frequently.
3. In rheumatologic practice, large numbers of patients present with generalized joint hypermobility [Beighton et al., 1983]. It is important to distinguish these individuals from those affected with the hypermobility type of EDS. There is considerable debate as to the causal interrelation-

ships, if any, between the phenotypes in such persons and in those with the hypermobility type of EDS.

4. Musculoskeletal pain is early in onset, chronic, and possibly debilitating [Sacheti et al., 1997]. The anatomical distribution is wide and tender points can sometimes be elicited. A tender point is defined as an area that, when palpated with the thumb or 2 or 3 fingers, will be painful at a pressure of 4 kg or less [Wolf et al., 1990].
5. For management, see Steinmann et al. [1993].

3) *Vascular type.* The vascular type of EDS is caused by structural defects in the pro α 1(III) chain of collagen type III encoded by COL3A1.

i) Inheritance.

Autosomal dominant.

ii) Major diagnostic criteria.

Thin, translucent skin.
Arterial/intestinal/uterine fragility or rupture.
Extensive bruising.
Characteristic facial appearance.

iii) Minor diagnostic criteria.

Acrogeria.
Hypermobility of small joints.
Tendon and muscle rupture.
Talipes equinovarus (clubfoot).
Early-onset varicose veins.
Arteriovenous, carotid-cavernous sinus fistula.
Pneumothorax/pneumohemothorax.
Gingival recession.
Positive family history, sudden death in (a) close relative(s).

The presence of any two or more of the major criteria is highly indicative of the diagnosis, and laboratory testing is strongly recommended.

iv) Cause and laboratory diagnosis. The method of laboratory diagnosis involves: 1) the demonstration of

structurally abnormal collagen type III produced by fibroblasts causing defective secretion, posttranslational overmodification, thermal instability, and/or sensitivity to proteases, and 2) the demonstration of a mutation in the COL3A1 gene [Steinmann et al., 1993].

Determination of the serum level of procollagen type III aminopropeptide is experimental because of biological variability, confounding concomitant conditions, and analytical modification of the assay necessary for the detection of low levels [Steinmann et al., 1989].

v) Specific comments.

1. Facial appearance is characteristic in some affected individuals (Fig. 1). There is a decrease in the subcutaneous adipose tissue, particularly in the face and limbs.
2. Joint hypermobility is usually limited to the digits.
3. Spontaneous arterial rupture has a peak incidence in the third or fourth decade of life but may occur earlier. Midsized arteries are most commonly involved. Arterial rupture is the most common cause of sudden death [Pepin et al., 1992].
4. Acute abdominal and flank pain (diffuse or localized) is a common presentation of arterial or intestinal rupture and should be investigated urgently. Noninvasive diagnostic procedures are recommended.



Fig. 1. Facial appearance in the arterial type is often quite typical, with a thin, delicate, and pinched nose; thin lips; tight skin; hollow cheeks and prominent staring eyes because of a paucity of adipose tissue; and tight, firm, lobeless ears. However, in some patients the facial characteristics are less apparent and even less so in children [Steinmann et al., 1993].

5. The subcutaneous venous pattern is particularly apparent over the chest and abdomen.
6. In the presence of severe bruising as an initial complication, child abuse and/or hematological disorders need to be considered. In the context of chronic bruising and abnormal scar formation, differentiation from the classical type of EDS is necessary.
7. Diagnosis of this condition is difficult in children in the absence of a family history.
8. Pregnancies may be complicated by intrapartum uterine rupture and pre- and postpartum arterial bleeding. Vaginal and perineal tears may be sustained during delivery.
9. Complications during and after surgery (e.g., wound dehiscence) are frequent and severe.
10. For management, see Steinmann et al. [1993].

4) Kyphoscoliosis type. This is caused by a deficiency of lysyl hydroxylase (PLOD), a collagen-modifying enzyme. Homozygosity or compound heterozygosity for mutant PLOD allele(s) results in the deficiency.

i) Inheritance.

Autosomal recessive.

ii) Major diagnostic criteria.

Generalized joint laxity.

Severe muscle hypotonia at birth.

Scoliosis at birth, progressive.

Scleral fragility and rupture of the ocular globe.

iii) Minor diagnostic criteria.

Tissue fragility, including atrophic scars.

Easy bruising.

Arterial rupture.

Marfanoid habitus.

Microcornea.

Radiologically considerable osteopenia.

Family history, i.e., affected sibs.

The presence of three major criteria in an infant is suggestive of the diagnosis, and laboratory testing is warranted.

iv) Cause and laboratory diagnosis. The recommended laboratory test is the measurement of total urinary hydroxylysyl pyridinoline ("Pyridinoline") and lysyl pyridinoline ("Deoxypyridinoline") crosslinks after hydrolysis by HPLC, a test which is readily available and has a very high degree of sensitivity and specificity [Steinmann et al., 1995]. The determination of dermal hydroxylysine is also easy; however, determination of lysyl hydroxylase activity in fibroblasts and/or mutational analysis of the PLOD gene is performed on a research basis only.

v) Specific comments.

1. Muscular hypotonia can be very pronounced and leads to delayed gross motor development. This condition should be considered in the initial differential diagnosis of a floppy infant [Wenstrup et al., 1989; Steinmann et al., 1993].

2. The phenotype is most often severe, frequently resulting in loss of ambulation in the second or third decade.
3. Scleral fragility may lead to rupture of the ocular globe after minor trauma. The condition should be differentiated from brittle cornea syndrome [Royce et al., 1990]. It is now apparent that serious eye complications are much less frequent than previously thought [Wenstrup et al., 1989; Steinmann et al., 1993], hence the change in the descriptor of this type.
4. The severe neonatal form of Marfan syndrome should be considered in the differential diagnosis.
5. There have been reports of a less severe form of the condition, with normal activity of lysyl hydroxylase and normal hydroxylysine content in the dermis (OMIM 229200); this form is even rarer.
6. For management, see Steinmann et al. [1993].

5) Arthrochalasia type. This is caused by mutations leading to deficient processing of the amino-terminal end of pro α 1(I) (type A) or pro α 2(I) (type B) chains of collagen type I because of skipping of exon 6 in either gene.

i) Inheritance.

Autosomal dominant.

ii) Major diagnostic criteria.

Severe generalized joint hypermobility, with recurrent subluxations.
Congenital bilateral hip dislocation.

iii) Minor diagnostic criteria.

Skin hyperextensibility.
Tissue fragility, including atrophic scars.
Easy bruising.
Muscle hypotonia.
Kyphoscoliosis.
Radiologically mild osteopenia.

iv) Cause and laboratory diagnosis. The biochemical defect is determined by electrophoretic demonstration of pN α 1(I) or pN α 2(I) chains extracted from dermal collagen or harvested from cultured skin fibroblasts. Direct demonstration of complete or partial exon 6 skipping in cDNAs of COL1A1 or COL1A2, respectively, can be performed, followed by mutation analysis [Steinmann et al., 1993].

v) Special comments.

1. Congenital hip dislocation has been present in all biochemically proven individuals.
2. Short stature is not a manifestation, unless it is a complication of severe kyphoscoliosis and/or hip dislocation.
3. Larsen syndrome should be considered in the differential diagnosis.
4. For management, see Steinmann et al. [1993].

6) Dermatosparaxis type. This is caused by defi-

ciency of procollagen I N-terminal peptidase, caused by homozygosity or compound heterozygosity of mutant alleles (in contrast to the arthrochalasia type, which is due to mutations involving the substrate sites of procollagen type I chains).

i) Inheritance.

Autosomal recessive.

ii) Major diagnostic criteria.

Severe skin fragility.
Sagging, redundant skin.

iii) Minor diagnostic criteria.

Soft, doughy skin texture.
Easy bruising.
Premature rupture of fetal membranes.
Large hernias (umbilical, inguinal).

iv) Cause and laboratory diagnosis. Biochemical confirmation is based on the electrophoretic demonstration of pN α 1(I) and pN α 2(I) chains from collagen type I extracted from dermis in the presence of protease inhibitors, or obtained from fibroblasts. Determination of N-proteinase activity is performed on a research basis only.

v) Special comments.

1. Skin fragility and bruising are substantial. Wound healing is not impaired, and the scars are not atrophic.
2. Redundancy of the facial skin results in an appearance resembling cutis laxa; however, bruising and skin fragility are not manifestations of cutis laxa.
3. The name was taken from a similar phenotype and biochemical defect previously recognized in cattle, sheep, and other animals.
4. The number of patients reported is small, and the phenotypic spectrum might expand.

Other Types of EDS

The current EDS type V (X-linked) was described in a single family [Beighton and Curtis, 1985].

The current EDS type VIII is similar to the classical type except that in addition it presents with periodontal friability [Stewart et al., 1977]. This is a rare type of EDS. The existence of this syndrome as an autonomous entity is uncertain.

EDS type IX was redefined previously as "occipital horn syndrome," an X-linked recessive condition allelic to Menkes syndrome (OMIM 309400) [Beighton et al., 1988].

The current EDS type X was described in one family only [Arneson et al., 1980; for comments, see Steinmann et al., 1993].

EDS type XI, termed "familial joint hypermobility syndrome," was previously removed from the EDS classification [Beighton et al., 1988]. Its relationship to EDS is not yet defined.

CONCLUDING REMARKS

The clinical variability and genetic heterogeneity of Ehlers-Danlos syndromes have long been recognized. The existing classification [Beighton et al., 1988] differentiates the various types of EDS on the basis of clinical manifestations and mode of inheritance. Although this approach is valid and useful, it relies heavily on the identification and subjective interpretation of signs that are semiquantitative, e.g., skin extensibility, joint hypermobility, tissue fragility, and bruising. The result is frequent diagnostic confusion regarding the type of EDS and the inclusion of phenotypically similar conditions under the broad diagnosis of EDS.

Since the publication of the existing classification, several reports described the clinical findings, natural history, and molecular basis of different types of EDS. This emerging information made apparent the somewhat artificial nature of the phenotypic boundaries between the former EDS type I and EDS type II. Another example is the frequent misdiagnosis of joint hypermobility as a type of EDS.

Thus, we revisited the existing Berlin classification with the following objectives: 1) to refine the diagnostic definitions by introducing diagnostic criteria based on the specificity of the various clinical manifestations for each type of the EDS; 2) to formalize the use of laboratory findings, whenever possible, in the diagnostic definition of each type; and 3) to simplify the existing EDS classification so that it becomes more accessible to the average generalist.

The proposed classification defines six major types of EDS. The descriptor captures, in our opinion, the pathognomonic manifestation of each type. Furthermore, the molecular basis of each of the proposed types either has been clearly defined or is emerging. Thus, we concluded that what was formerly known as EDS type I and EDS type II could be merged into a single entity, the proposed *classical type*, because recent evidence indicates that they can have a common cause such as mutations in the COL5A1 or COL5A2 genes. Furthermore, the earlier differentiation was based primarily on the extent of severity of skin manifestations, a trait that could be attributable to a phenotype/genotype correlation, and which was not necessarily a distinction based on cause. The diagnostic criteria proposed for the *hypermobility type* will permit clear distinction from other types of EDS and also from phenotypically related disorders. We define the *vascular type* of EDS on the basis of clinical manifestations and the presence of mutations in the COL3A1 gene. Similarly, we define the *Kyphoscoliosis*, *arthrochalasia*, and *dermatosparaxis types* on the basis of clinical manifestations and the presence of particular biochemical abnormalities or molecular defects. The former EDS type V is a rare variant, the molecular basis of which remains unknown. The clinical characteristics of the entity currently known as EDS type VIII remain uncertain; thus, its delineation will require more clinical and molecular information.

We hope that these revised criteria can serve as a new, albeit provisional, standard for clinical diagnosis of Ehlers-Danlos syndrome, for investigations of its ge-

netic heterogeneity and phenotype-genotype correlations, and for clinical research on various aspects of these conditions. A further aim of this paper is to provide diagnostic criteria which will allow a clearer distinction of disorders that partially overlap with EDS and aid their clinical identification and research evaluation.

ACKNOWLEDGMENTS

This endeavor was sponsored by the Ehlers-Danlos National Foundation (USA) and the Ehlers-Danlos Support Group (UK). Representatives of several national EDS groups held their own first international meeting at the time of writing. This promoted contacts, interaction, and exchange, making it possible for involved lay persons to provide valuable input into the development of concepts concerning EDS. The authors thank Drs. Peter Byers, William Cole, Michael Pope, Peter Royce, and Andrea Superti-Furga for reviewing and criticizing the manuscript.

REFERENCES

- Arneson MA, Hammerschmidt DE, Furcht LT, King RA (1980): A new form of Ehlers-Danlos syndrome. Fibronectin corrects defective platelet function. *JAMA* 244:144-147.
- Beighton P (1970): "The Ehlers-Danlos Syndrome." London: William Heinemann Medical Books, pp 1-194.
- Beighton P (1993): The Ehlers-Danlos syndromes. In Beighton P (ed) "Heritable Disorders of Connective Tissue," 5th ed. St. Louis: Mosby, pp 189-251.
- Beighton P, Curtis D (1985): X-linked Ehlers-Danlos syndrome type V: The next generation. *Clin Genet* 27:472-478.
- Beighton P, Horan FT (1960): Surgical aspects of the Ehlers-Danlos syndrome. A survey of 100 cases. *Br J Surg* 56:255-259.
- Beighton P, Horan F (1969): Orthopaedic aspects of the Ehlers-Danlos syndrome. *J Bone Joint Surg [Br]* 51:444-453.
- Beighton P, Grahame R, Bird H (1989): "Hypermobility of Joints," 2nd edition. Berlin: Springer, pp 1-182.
- Beighton P, De Paepe A, Danks D, Finidori G, Gedde-Dahl T, Goodman R, Hall JG, Hollister DW, Horton W, McKusick VA, Opitz JM, Pope FM, Pyeritz RE, Rimoin DL, Sillence D, Spranger JW, Thompson E, Tsipouras P, Viljoen D, Winship I, Young I (1988): International nosology of heritable disorders of connective tissue, Berlin, 1986. *Am J Med Genet* 29:581-594.
- Devereux RB, Kramer-Fox R, Shear MK, Kligfield P, Pini R, Savage DD (1987): Diagnosis and classification of severity of mitral valve prolapse: Methodologic, biologic and prognostic considerations. *Am Heart J* 113:1265-1280.
- Hausser I, Anton-Lamprecht I (1994): Differential ultrastructural aberrations of collagen fibrils in Ehlers-Danlos syndrome types I-IV as a means of diagnostics and classification. *Hum Genet* 93:394-407.
- Leier CV, Call TD, Fulkerson PK, Wooley CF (1980): The spectrum of cardiac defects in the Ehlers-Danlos syndrome, types I and III. *Ann Intern Med* 92:171-178.
- McKusick VA (1972): The Ehlers-Danlos syndrome. In: "Heritable Disorders of Connective Tissue," 4th ed. St. Louis: C.V. Mosby, pp 292-371.
- Pepin MG, Superti-Furga A, Byers PH (1992): Natural history of Ehlers-Danlos syndrome type IV (EDS type IV): Review of 137 cases. *Am J Hum Genet* 51:44.
- Roman MJ, Devereux RB, Kramer-Fox R, O'Ranghlin J (1989): Two-dimensional aortic root dimensions in normal children and adults. *Am J Cardiol* 64:507-512.
- Roman MJ, Rosen SS, Kramer-Fox R, Devereux RB (1993): The prognostic significance of the pattern of aortic root dilatation in the Marfan syndrome. *J Am Coll Cardiol* 22:1470-1476.
- Royce PM, Steinmann B, Vogel A, Steinhorst U, Kohlschuetter A (1990): Brittle cornea syndrome: A heritable connective tissue disorder distinct from Ehlers-Danlos syndrome type VI and fragilitas oculi, with spontaneous perforations of the eye, blue sclerae, red hair and normal collagen lysyl hydroxylation. *Eur J Pediatr* 149:465-469.

- Sacheti A, Szemere J, Bernstein B, Tafas T, Schechter N, Tsiouras P (1997): Chronic pain is a manifestation of the Ehlers-Danlos syndrome. *J Pain Symptom Managem* 14:88–93.
- Sorokin Y, Johnson MP, Rogowski N, Richardson DA, Evans MI (1994): Obstetric and gynecologic dysfunction in the Ehlers-Danlos syndrome. *J Reprod Med* 39:281–284.
- Steinmann B, Superti-Furga A, Joller-Jemelka HJ, Cetta G, Byers PH (1989): Ehlers-Danlos syndrome type IV: A subset of patients distinguished by low serum levels of the amino-terminal propeptide of type III procollagen. *Am J Med Genet* 34:68–71.
- Steinmann B, Royce PM, Superti-Furga A (1993): The Ehlers-Danlos syndrome. In Royce PM, Steinmann B (ed): "Connective Tissue and its Heritable Disorders: Molecular, Genetic and Medical Aspects." New York: Wiley-Liss, pp 351–407.
- Steinmann B, Eyre DR, Shao P (1995): Urinary pyridinoline cross-links in Ehlers-Danlos syndrome type VI. *Am J Hum Genet* 57:1505–1508.
- Stewart RE, Hollister DW, Rimo DL (1977): A New Variant of Ehlers-Danlos Syndrome: An Autosomal Dominant Disorder of Fragile Skin, Abnormal Scarring and Generalized Periodontitis. *BD: OAS XIII (3B):85–93.*
- Vogel A, Holbrook KA, Steinmann B, Gitzelmann R, Byers PH (1979): Abnormal collagen fibril structure in the gravis form (type I) of the Ehlers-Danlos syndrome. *Lab Invest* 40:201–206.
- Wenstrup RJ, Murad S, Pinnell SR (1989): Ehlers-Danlos syndrome type VI: Clinical manifestations of collagen lysyl hydroxylase deficiency. *J Pediatr* 115:405–409.
- Wolf F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, Tugwell P, Campbell SM, Abeles M, Clark P, Fam AG, Farber SJ, Fiechtner JJ, Franklin CM, Gatter RA, Hamaty D, Lessard J, Lichtbroun AS, Masi AT, McCain GA, Reynolds WJ, Romano TJ, Russell LJ, Sheon RP (1990): The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. *Arthritis Rheum* 33:160–172.